AstraZeneca And HUTCHMED’s Savolitinib, In Combination With TAGRISSO, Delivers Significant Survival Benefits In SAFFRON Phase III EGFRm Lung Cancer Trial

뉴스 본문을 불러오고 있어요.

AstraZeneca And HUTCHMED’s Savolitinib, In Combination With TAGRISSO, Delivers Significant Survival Benefits In SAFFRON Phase III EGFRm Lung Cancer Trial | 웨이프 WAPE

AstraZeneca And HUTCHMED’s Savolitinib, In Combination With TAGRISSO, Delivers Significant Survival Benefits In SAFFRON Phase III EGFRm Lung Cancer Trial

기사 요약

관련 종목

댓글 —